Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 3Thoracic 1Head & Neck 1

Conditions

Brain Neoplasms 3Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × 5-fluoropentyl-2-methylmalonic acid × Clear all
NCT00696943 2013-02-15

18F ML-10 for Early Detection of Response of Brain Metastases to SRS

Aposense Ltd.

Phase 2 Terminated
1 enrolled
CNS

Brain Neoplasms

NCT00791063 2013-02-13

18F ML-10 for Early Detection of Response of Brain Metastases to WBRT

Aposense Ltd.

Phase 2 Completed
10 enrolled
CNS

Brain Neoplasms

NCT01260480 2010-12-17

An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

Aposense Ltd.

Phase 2 Unknown
60 enrolled
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00805636 2010-05-12

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Aposense Ltd.

Phase 2 Unknown
30 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡